Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc BIOYF


Primary Symbol: V.RX

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent Releases Financial Results for Q3 and YTD 2024

GlobeNewswire 2 days ago

BioSyent Declares Fourth Quarter 2024 Dividend

GlobeNewswire 2 days ago

BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024

GlobeNewswire 8 days ago

BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets

GlobeNewswire September 20, 2024

BioSyent Releases Financial Results for Q2 and H1 2024

GlobeNewswire August 26, 2024

BioSyent Declares Third Quarter 2024 Dividend

GlobeNewswire August 26, 2024

BioSyent In-Licenses Endocrinology Product for Canada

GlobeNewswire June 12, 2024

BioSyent Releases Financial Results for Q1 2024

GlobeNewswire May 16, 2024

BioSyent Declares Second Quarter 2024 Dividend

GlobeNewswire May 16, 2024

BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024

GlobeNewswire May 9, 2024

BioSyent to Attend Planet MicroCap Showcase

GlobeNewswire April 23, 2024

BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

GlobeNewswire April 15, 2024

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 10, 2024

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year

GlobeNewswire April 3, 2024

BioSyent to Present at LD Micro New York Investor Conference

GlobeNewswire April 1, 2024

BioSyent Announces Grant of Restricted Share Units

GlobeNewswire March 27, 2024

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

GlobeNewswire March 13, 2024

BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

GlobeNewswire March 6, 2024

BioSyent Named to 2024 TSX Venture 50

GlobeNewswire February 21, 2024

BioSyent Declares First Quarter 2024 Dividend

GlobeNewswire February 6, 2024